文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

Pluralibacter gergoviae的临床相关性及抗菌药物耐药性:系统综述

The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该系统综述汇总34项研究共196例患者,显示Pluralibacter gergoviae感染多为医疗相关(66%),以ICU(74%)和新生儿ICU(70%)为主,血流感染最常见。33%菌株为多重耐药,ESBL和碳青霉烯酶检出率分别为35%和23%,死亡率为11%,既往抗生素使用与死亡显著相关(P=0.039;OR=13)。

要点

  • P. gergoviae感染罕见但多见于ICU和新生儿ICU,血流感染最常见。
  • 33%菌株多重耐药,ESBL和碳青霉烯酶检出率分别为35%和23%。
  • 死亡率11%,既往抗生素使用与死亡显著相关(P=0.039;OR=13)。

核心结论

  • Pluralibacter gergoviae感染虽罕见但具有临床相关性,存在多重耐药潜力,对脆弱人群尤其是新生儿ICU患者影响显著。

研究设计与样本

  • 系统综述,检索多个数据库及灰色文献无时间限制,最终纳入34项研究(16篇文献检索+18项灰色文献/手动检索),共196例确诊患者。

主要发现

  • 196例患者中男性占59%,医疗相关感染占66%,ICU入住占74%,新生儿ICU占70%。
  • 血流感染最常见,其次为牙周炎和尿路感染。
  • 多重耐药菌株占33%,ESBL和碳青霉烯酶产生率分别为35%和23%。
  • 最常见的碳青霉烯酶基因为blaKPC、blaNDM和blaIMP。
  • 死亡率为11%,所有多重耐药相关死亡均与blaKPC相关;既往抗生素使用与死亡显著相关(P=0.039;OR=13)。

关键数值与推荐

  • 多重耐药定义为33%的菌株;ESBL阳性35%;碳青霉烯酶阳性23%。
  • 死亡11%;既往抗生素使用与死亡的OR为13(P=0.039)。

临床怎么用

  • 对ICU和新生儿ICU患者应警惕P. gergoviae感染,尤其血流感染。
  • 经验性抗菌治疗需考虑多重耐药风险,碳青霉烯酶基因型(blaKPC、blaNDM、blaIMP)检测有助于指导治疗。
  • 既往抗生素使用是死亡危险因素,应优化抗菌药物管理。

局限性

  • 纳入研究多为病例报告和小样本系列,存在发表偏倚可能。
  • 表型方法主要用于菌种鉴定,分子分型数据有限。
  • 缺乏统一的多重耐药定义和临床结局标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pluralibacter gergoviae is a gram-negative bacillus in the Enterobacteriaceae family. Although rarely associated with human infections, its resistance to preservatives and presence in hospital-use products raise concerns about nosocomial transmission. OBJECTIVES: To describe the clinical and microbiological profiles of P. gergoviae infections. METHODS: A comprehensive search was conducted in multiple databases and grey literature without time restrictions. Eligibility criteria included: (1) studies reporting human infections by P. gergoviae and (2) patients with confirmed infections. Data were synthesized narratively and summarized as frequencies and proportions. Univariate and multivariate analyses assessed risk factors for multidrug resistance (MDR) and mortality. RESULTS: Of 371 articles retrieved, 16 met the inclusion criteria, and 18 additional studies were identified through grey literature and manual search, totalling 34 studies. Three described outbreaks, two in neonatal intensive care units (NICUs). Overall, 196 patients were identified, predominantly male (59%), with 66% of infections being healthcare-associated. Most were admitted to ICUs (74%), especially NICUs (70%). Bloodstream infections were most common, followed by periodontitis and urinary tract infections. Phenotypic methods were primarily used for identification. MDR was reported in 33% of strains; ESBL and carbapenemase production in 35% and 23% of cases, respectively. The most frequent carbapenemase genes were blaKPC, blaNDM, and blaIMP. Mortality occurred in 11% of cases, and all MDR-related deaths were associated with blaKPC. Prior antibiotic use was significantly associated with mortality (P = 0.039; OR: 13). CONCLUSIONS: Pluralibacter gergoviae is rare but clinically relevant, with MDR potential and impact on vulnerable populations, particularly in NICU settings.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Saad BAA, Volpe-Chaves CE, de Oliveira CTF, et al. The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review. J Antimicrob Chemother. 2026. PMID: 41549661. doi:10.1093/jac/dkaf476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。